Literature DB >> 19114675

Bronchopulmonary disposition of micafungin in healthy adult volunteers.

Anthony M Nicasio1, Pamela R Tessier, David P Nicolau, R Fredrick Knauft, John Russomanno, Eric Shore, Joseph L Kuti.   

Abstract

By way of bronchoscopy and bronchoalveolar lavage, intrapulmonary steady-state concentrations of micafungin administered at 150 mg daily to 15 healthy volunteers were determined at 4, 12, and 24 h after the third dose. The micafungin disposition was predominantly intracellular, with approximately 106% penetration into alveolar macrophages and 5% penetration into epithelial lining fluid.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19114675      PMCID: PMC2650581          DOI: 10.1128/AAC.01386-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

Review 1.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

2.  Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction.

Authors:  Mary F Hebert; Helen E Smith; Thomas C Marbury; Suzanne K Swan; William B Smith; Robert W Townsend; Donald Buell; James Keirns; Ihor Bekersky
Journal:  J Clin Pharmacol       Date:  2005-10       Impact factor: 3.126

Review 3.  Changing patterns and trends in systemic fungal infections.

Authors:  Malcolm D Richardson
Journal:  J Antimicrob Chemother       Date:  2005-09       Impact factor: 5.790

Review 4.  Aspergillosis case-fatality rate: systematic review of the literature.

Authors:  S J Lin; J Schranz; S M Teutsch
Journal:  Clin Infect Dis       Date:  2001-01-26       Impact factor: 9.079

5.  Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state.

Authors:  John E Conte; Jeffrey A Golden; Juliana Kipps; Marina McIver; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

6.  Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults.

Authors:  Blair Capitano; Holly M Mattoes; Eric Shore; Aidan O'Brien; Sidney Braman; Chistina Sutherland; David P Nicolau
Journal:  Chest       Date:  2004-03       Impact factor: 9.410

7.  Combination antifungal therapy for invasive aspergillosis.

Authors:  Kieren A Marr; Michael Boeckh; Rachel A Carter; Hyung Woo Kim; Lawrence Corey
Journal:  Clin Infect Dis       Date:  2004-08-27       Impact factor: 9.079

8.  Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity.

Authors:  Nathan P Wiederhold; Dimitrios P Kontoyiannis; Jingduan Chi; Randall A Prince; Vincent H Tam; Russell E Lewis
Journal:  J Infect Dis       Date:  2004-09-10       Impact factor: 5.226

9.  Role of plasma proteins in pharmacokinetics of micafungin, an antifungal antibiotic, in analbuminemic rats.

Authors:  Fumie Abe; Jun Ueyama; Noriyo Kawasumi; Masayuki Nadai; Tamon Hayashi; Miki Kato; Masafumi Ohnishi; Hiroko Saito; Naoshi Takeyama; Takaaki Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

10.  Phagocytosis and intracellular fate of Aspergillus fumigatus conidia in alveolar macrophages.

Authors:  O Ibrahim-Granet; B Philippe; H Boleti; E Boisvieux-Ulrich; D Grenet; M Stern; J P Latgé
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

View more
  13 in total

1.  Mutant Prevention Concentration and Mutant Selection Window of Micafungin and Anidulafungin in Clinical Candida glabrata Isolates.

Authors:  Pilar Escribano; Jesús Guinea; María Ángeles Bordallo-Cardona; Laura Judith Marcos-Zambrano; Carlos Sánchez-Carrillo; Elia Gómez G de la Pedrosa; Rafael Cantón; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

Review 2.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

3.  Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients.

Authors:  Thomas J Walsh; Sylvain Goutelle; Roger W Jelliffe; Jeffrey A Golden; Emily A Little; Catherine DeVoe; Diana Mickiene; Maggie Hayes; John E Conte
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

Review 4.  Echinocandin antifungal drugs in fungal infections: a comparison.

Authors:  Sharon C-A Chen; Monica A Slavin; Tania C Sorrell
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

5.  Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry.

Authors:  Fedja Farowski; Oliver A Cornely; Jörg J Vehreschild; Pia Hartmann; Tim Bauer; Angela Steinbach; Maria J G T Rüping; Carsten Müller
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

Review 6.  Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents.

Authors:  Keith A Rodvold; Liz Yoo; Jomy M George
Journal:  Clin Pharmacokinet       Date:  2011-11-01       Impact factor: 6.447

7.  Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.

Authors:  Jared L Crandon; Mary Anne Banevicius; Annie F Fang; Penelope H Crownover; R Fredrick Knauft; J Samuel Pope; John H Russomanno; Eric Shore; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

Review 8.  Micafungin for Candida albicans pacemaker-associated endocarditis: a case report and review of the literature.

Authors:  Carlo Tascini; Maria Grazia Bongiorni; Enrico Tagliaferri; Antonello Di Paolo; Sarah Flammini; Ezio Soldati; Alessandro Leonildi; Andrea Di Cori; Francesco Menichetti
Journal:  Mycopathologia       Date:  2012-10-17       Impact factor: 2.574

9.  Pulmonary epithelial lining fluid concentrations after use of systemic amphotericin B lipid formulations.

Authors:  Stefan Weiler; Gerda Falkensammer; Angelika Hammerer-Lercher; Markus Anliker; Helene Vogelsinger; Michael Joannidis; Stefan Dunzendorfer; Markus Stein; Romuald Bellmann
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

Review 10.  Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2012-11-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.